Read the full release \u2192<\/a><\/p>\nNews provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced\u00a0common\u2026<\/p>\n","protected":false},"author":16,"featured_media":8372,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-design-inspiration"],"yoast_head":"\n
Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced\u00a0common\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T16:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Olivia Bennett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Olivia Bennett\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/\"},\"author\":{\"name\":\"Olivia Bennett\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/d8965f6a84e545dff628336ed24a52b0\"},\"headline\":\"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis\",\"datePublished\":\"2026-06-26T16:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/\"},\"wordCount\":72,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/default-image.jpg\",\"articleSection\":[\"Design Inspiration\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/\",\"name\":\"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/default-image.jpg\",\"datePublished\":\"2026-06-26T16:35:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/d8965f6a84e545dff628336ed24a52b0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/default-image.jpg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/default-image.jpg\",\"width\":384,\"height\":253,\"caption\":\"Default image\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/d8965f6a84e545dff628336ed24a52b0\",\"name\":\"Olivia Bennett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Olivia-Bennett-1-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Olivia-Bennett-1-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Olivia-Bennett-1-96x96.jpeg\",\"caption\":\"Olivia Bennett\"},\"description\":\"Olivia Bennett writes about the people, ideas, and creative movements shaping contemporary arts and culture. Her work explores exhibitions, artists, creative communities, and the stories behind visual expression. With an accessible and observant writing style, Olivia enjoys connecting individual works of art with the larger cultural conversations surrounding creativity, identity, place, and community.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/olivia-bennett\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte","og_description":"New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced\u00a0common\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-26T16:35:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Olivia Bennett","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Olivia Bennett"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/"},"author":{"name":"Olivia Bennett","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/d8965f6a84e545dff628336ed24a52b0"},"headline":"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis","datePublished":"2026-06-26T16:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/"},"wordCount":72,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","articleSection":["Design Inspiration"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/","name":"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","datePublished":"2026-06-26T16:35:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/d8965f6a84e545dff628336ed24a52b0"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","width":384,"height":253,"caption":"Default image"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson presents new IMAAVY\u00ae (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/d8965f6a84e545dff628336ed24a52b0","name":"Olivia Bennett","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Olivia-Bennett-1-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Olivia-Bennett-1-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/Olivia-Bennett-1-96x96.jpeg","caption":"Olivia Bennett"},"description":"Olivia Bennett writes about the people, ideas, and creative movements shaping contemporary arts and culture. Her work explores exhibitions, artists, creative communities, and the stories behind visual expression. With an accessible and observant writing style, Olivia enjoys connecting individual works of art with the larger cultural conversations surrounding creativity, identity, place, and community.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/olivia-bennett\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=2669"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2669\/revisions"}],"predecessor-version":[{"id":9293,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2669\/revisions\/9293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/8372"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=2669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=2669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=2669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}